

Supplementary figure and table legends

Supplementary figure 1 Infectious mortality among patients diagnosed with cancer between 1975 and 2016 in SEER 18 registries by time since cancer diagnosis and anatomic sites.

Supplementary figure 2 Trends of cancer-related deaths and infectious deaths by time after diagnosis among patients diagnosed with cancer. (A) Trends of cancer-related deaths by time after diagnosis among patients diagnosed with cancer; (B) trends of infectious deaths by time after diagnosis among patients diagnosed with cancer.

Supplementary figure 3 Cumulative mortality rate of fatal infection among patients diagnosed with cancer.

Supplementary figure 4 Cumulative mortality rate of fatal infection by chemotherapy among patients diagnosed with cancer. (A) Follow up to 20 years after cancer diagnosis; (B) follow up to 10 years after cancer diagnosis.


Supplementary table 1 Mortality from pneumonia and influenza among patients diagnosed with cancer between 1975 and 2016 in SEER 18 registries by anatomic sites.

Supplementary table 2 Mortality from syphilis among patients diagnosed with cancer between 1975 and 2016 in SEER 18 registries by anatomic sites.


Supplementary table 3 Mortality from tuberculosis among patients diagnosed with cancer between 1975 and 2016 in SEER 18 registries by anatomic sites.

Supplementary table 4 Mortality from septicemia among patients diagnosed with cancer between 1975 and 2016 in SEER 18 registries by anatomic sites.


Supplementary table 5 Mortality from other infectious and parasitic diseases including HIV among patients diagnosed with cancer between 1975 and 2016 in SEER 18 registries by anatomic sites.




Supplementary figure 1 Infectious mortality among patients diagnosed with cancer between 1975 and 2016 in SEER 18 registries by time since cancer diagnosis and anatomic sites.



Supplementary figure 2 Trends of cancer-related deaths and infectious deaths by time after diagnosis among patients diagnosed with cancer. (A) Trends of cancer-related deaths by time after diagnosis among patients diagnosed with cancer; (B) trends of infectious deaths by time after diagnosis among patients diagnosed with cancer.



Supplementary figure 3 Cumulative mortality rate of fatal infection among patients diagnosed with cancer.



Supplementary figure 4 Cumulative mortality rate of fatal infection by chemotherapy among patients diagnosed with cancer. (A) Follow up to 20 years after cancer diagnosis; (B) follow up to 10 years after cancer diagnosis.

Supplementary table 1 Mortality from pneumonia and influenza among patients diagnosed with cancer between 1975 and 2016 in SEER 18 registries by anatomic sites.

Anatomic sites	No. of patients with cancer (%)	Total person years of follow-up	Death from pneumonia and influenza				SMR (95% CI)
			Patients with cancer		General population		
			No. of observed deaths (%)	Mortality rates (per 100,000 person-years)	No. of expected deaths	Mortality rates (per 100,000 person-years)	
All sites	8,471,051 (100%)	51,747,254	61,773 (100%)	119.4	25999.3	50.2	2.38 (2.36-2.39)
Acute lymphocytic leukemia	30,933 (0.4%)	234,167	68 (0.1%)	29.0	6.2	2.7	10.9 (8.60-13.8)
Brain	123,661 (1.5%)	459,463	443 (0.7%)	96.4	44.7	9.7	9.90 (9.02-10.9)
Acute myeloid leukemia	61,060 (0.7%)	144,730	285 (0.5%)	196.9	28.9	20.0	9.85 (8.77-11.1)
Hodgkin lymphoma	53,532 (0.6%)	547,268	270 (0.4%)	49.3	41.5	7.6	6.50 (5.77-7.33)
Esophagus	73,170 (0.9%)	136,295	461 (0.7%)	338.2	83.2	61.1	5.54 (5.06-6.07)
Kaposi sarcoma	22,244 (0.3%)	98,175	182 (0.3%)	185.4	33.2	33.8	5.48 (4.74-6.34)
Lung and bronchus	965,341 (11.4%)	1,812,077	5,305 (8.6%)	292.8	1088.6	60.1	4.87 (4.74-5.01)
Myeloma	101,626 (1.2%)	351,116	995 (1.6%)	283.4	218.7	62.3	4.55 (4.27-4.84)
Chronic myeloid leukemia	29,392 (0.3%)	133,063	241 (0.4%)	181.1	55.3	41.6	4.36 (3.84-4.94)
Oral cavity and pharynx	194,033 (2.3%)	1,125,688	1,992 (3.2%)	177.0	478.3	42.5	4.16 (3.99-4.35)
Testis	53,702 (0.6%)	630,100	83 (0.1%)	13.2	21.9	3.5	3.79 (3.05-4.69)
Cervix uteri	87,411 (1.0%)	766,854	356 (0.6%)	46.4	95.4	12.4	3.73 (3.36-4.14)
Larynx	69,152 (0.8%)	452,396	847 (1.4%)	187.2	228.8	50.6	3.70 (3.46-3.96)
Liver	118,324 (1.4%)	178,460	249 (0.4%)	139.5	67.4	37.8	3.69 (3.26-4.18)
Bones and joints	16,674 (0.2%)	129,231	52 (0.1%)	40.2	14.6	11.3	3.55 (2.71-4.66)
Pancreas	195,663 (2.3%)	184,030	422 (0.7%)	229.3	125.7	68.3	3.36 (3.05-3.69)
Stomach	138,776 (1.6%)	362,179	928 (1.5%)	256.2	289.4	79.9	3.21 (3.01-3.42)

Chronic lymphocytic leukemia	75,640 (0.9%)	469,838	1,169 (1.9%)	248.8	370.9	78.9	3.15 (2.98-3.34)
Non-Hodgkin lymphoma	311,485 (3.7%)	1,782,298	2,497 (4.0%)	140.1	820.5	46.0	3.04 (2.93-3.17)
Vulva	48,635 (0.6%)	437,415	360 (0.6%)	82.3	127.1	29.1	2.83 (2.55-3.14)
Corpus uteri	250,987 (3.0%)	2,179,474	1,921 (3.1%)	88.1	680.2	31.2	2.82 (2.70-2.95)
Anus	34,322 (0.4%)	205,924	169 (0.3%)	82.1	66.5	32.3	2.54 (2.19-2.96)
Kidney and renal pelvis	219,761 (2.6%)	1,257,816	1,307 (2.1%)	103.9	525.7	41.8	2.49 (2.36-2.62)
Ovary	131,819 (1.6%)	754,837	424 (0.7%)	56.2	179.1	23.7	2.37 (2.15-2.60)
Small intestine	29,300 (0.3%)	144,653	152 (0.2%)	105.1	66.0	45.6	2.30 (1.96-2.70)
Cranial nerves other nervous system	124,837 (1.5%)	617,984	597 (1.0%)	96.6	259.5	42.0	2.30 (2.12-2.49)
Endocrine system	243,115 (2.9%)	1,955,341	564 (0.9%)	28.8	247.2	12.6	2.28 (2.10-2.48)
Colon and rectum	836,720 (9.9%)	5,080,314	8,783 (14.2%)	172.9	4021.1	79.2	2.18 (2.14-2.23)
Soft tissue including heart	51,819 (0.6%)	350,729	237 (0.4%)	67.6	113.1	32.3	2.09 (1.84-2.38)
Breast	1,385,735 (16.4%)	12,017,682	8,674 (14.0%)	72.2	4186.0	34.8	2.07 (2.03-2.12)
Urinary bladder	310,644 (3.7%)	2,115,298	3,716 (6.0%)	175.7	1817.6	85.9	2.04 (1.98-2.11)
Eye and orbit	16,780 (0.2%)	141,603	116 (0.2%)	81.9	59.8	42.3	1.94 (1.62-2.33)
Prostate	1,153,981 (13.6%)	9,095,242	12,344 (20.0%)	135.7	7132.6	78.4	1.73 (1.70-1.76)
Skin, non-basal	494,208 (5.8%)	4,146,605	2,578 (4.2%)	62.2	1610.3	38.8	1.60 (1.54-1.66)

Supplementary table 2 Mortality from syphilis among patients diagnosed with cancer between 1975 and 2016 in SEER 18 registries by anatomic sites.

Anatomic sites	No. of patients with cancer (%)	Total person years of follow-up	Death from syphilis				
			Patients with cancer		General population		SMR (95% CI)
			No. of observed deaths (%)	Mortality rates (per 100,000 person-years)	No. of expected deaths	Mortality rates (per 100,000 person-years)	
All	8,471,051 (100%)	51,747,254	27 (100.0%)	0.05	15.58	0.03	1.73 (1.19-2.53)
Acute lymphocytic leukemia	30,933 (0.4%)	234,167	1 (3.7%)	0.43	0.00	0.00	243.2 (34.3-1,726.2)
Cranial nerves other nervous system	124,837 (1.5%)	617,984	1 (3.7%)	0.16	0.06	0.01	18.0 (2.53-127.6)
Soft tissue including heart	51,819 (0.6%)	350,729	1 (3.7%)	0.29	0.07	0.02	13.9 (1.96-98.6)
Endocrine system	243,115 (2.9%)	1,955,341	1 (3.7%)	0.05	0.10	0.01	9.53 (1.34-67.7)
Kidney and renal pelvis	219,761 (2.6%)	1,257,816	2 (7.4%)	0.16	0.29	0.02	6.91 (1.73-27.6)
Larynx	69,152 (0.8%)	452,396	1 (3.7%)	0.22	0.25	0.05	4.04 (0.57-28.7)
Urinary bladder	310,644 (3.7%)	2,115,298	3 (11.1%)	0.14	1.04	0.05	2.89 (0.93-8.95)
Lung and bronchus	965,341 (11.4%)	1,812,077	2 (7.4%)	0.11	0.74	0.04	2.71 (0.68-10.8)
Breast	1,385,735 (16.4%)	12,017,682	4 (14.8%)	0.03	1.98	0.02	2.02 (0.76-5.39)
Corpus uteri	250,987 (3.0%)	2,179,474	1 (3.7%)	0.05	0.51	0.02	1.98 (0.28-14.0)
Prostate	1,153,981 (13.6%)	9,095,242	7 (25.9%)	0.08	5.06	0.06	1.38 (0.66-2.90)
Colon and rectum	836,720 (9.9%)	5,080,314	2 (7.4%)	0.04	2.67	0.05	0.75 (0.19-3.00)

Supplementary table 3 Mortality from tuberculosis among patients diagnosed with cancer between 1975 and 2016 in SEER 18 registries by anatomic sites.

Anatomic sites	No. of patients with cancer (%)	Total person years of follow-up	Death from tuberculosis				SMR (95% CI)
			Patients with cancer		General population		
			No. of observed deaths (%)	Mortality rates (per 100,000 person-years)	No. of expected deaths	Mortality rates (per 100,000 person-years)	
All	8,471,051 (100%)	51,747,254	711 (100%)	1.37	527.9	1.02	1.35 (1.25-1.45)
Kaposi sarcoma	22,244 (0.3%)	98,175	13 (1.8%)	13.2	0.77	0.78	17.0 (9.84-29.2)
Acute lymphocytic leukemia	30,933 (0.4%)	234,167	1 (0.1%)	0.43	0.11	0.05	9.14 (1.29-64.9)
Liver	118,324 (1.4%)	178,460	14 (2.0%)	7.84	1.85	1.04	7.56 (4.48-12.8)
Chronic myeloid leukemia	29,392 (0.3%)	133,063	5 (0.7%)	3.76	0.99	0.74	5.07 (2.11-12.2)
Lung and bronchus	965,341 (11.4%)	1,812,077	111 (15.6%)	6.13	24.1	1.33	4.60 (3.82-5.54)
Esophagus	73,170 (0.9%)	136,295	8 (1.1%)	5.87	1.79	1.31	4.47 (2.24-8.95)
Acute myeloid leukemia	61,060 (0.7%)	144,730	2 (0.3%)	1.38	0.65	0.45	3.08 (0.77-12.3)
Vulva	48,635 (0.6%)	437,415	5 (0.7%)	1.14	1.82	0.42	2.75 (1.14-6.60)
Cervix uteri	87,411 (1.0%)	766,854	9 (1.3%)	1.17	3.33	0.43	2.70 (1.41-5.20)
Non-Hodgkin lymphoma	311,485 (3.7%)	1,782,298	37 (5.2%)	2.08	14.6	0.82	2.53 (1.83-3.49)
Myeloma	101,626 (1.2%)	351,116	11 (1.5%)	3.13	4.55	1.30	2.42 (1.34-4.37)
Oral cavity and pharynx	194,033 (2.3%)	1,125,688	29 (4.1%)	2.58	12.2	1.08	2.37 (1.65-3.42)
Anus	34,322 (0.4%)	205,924	3 (0.4%)	1.46	1.28	0.62	2.34 (0.75-7.25)
Hodgkin lymphoma	53,532 (0.6%)	547,268	3 (0.4%)	0.55	1.37	0.25	2.18 (0.70-6.77)
Stomach	138,776 (1.6%)	362,179	17 (2.4%)	4.69	7.86	2.17	2.16 (1.34-3.48)
Brain	123,661 (1.5%)	459,463	2 (0.3%)	0.44	1.01	0.22	1.99 (0.50-7.94)
Eye and orbit	16,780 (0.2%)	141,603	2 (0.3%)	1.41	1.02	0.72	1.95 (0.49-7.81)
Pancreas	195,663 (2.3%)	184,030	4 (0.6%)	2.17	2.14	1.16	1.87 (0.70-4.97)
Chronic lymphocytic leukemia	75,640 (0.9%)	469,838	9 (1.3%)	1.92	5.74	1.22	1.57 (0.82-3.01)

Larynx	69,152 (0.8%)	452,396	11 (1.5%)	2.43	7.52	1.66	1.46 (0.81-2.64)
Endocrine system	243,115 (2.9%)	1,955,341	8 (1.1%)	0.41	6.28	0.32	1.27 (0.64-2.55)
Kidney and renal pelvis	219,761 (2.6%)	1,257,816	14 (2.0%)	1.11	11.4	0.91	1.23 (0.73-2.07)
Urinary bladder	310,644 (3.7%)	2,115,298	39 (5.5%)	1.84	32.8	1.55	1.19 (0.87-1.63)
Cranial nerves other nervous system	124,837 (1.5%)	617,984	3 (0.4%)	0.49	2.75	0.45	1.09 (0.35-3.38)
Breast	1,385,735 (16.4%)	12,017,682	71 (10.0%)	0.59	67.2	0.56	1.06 (0.84-1.33)
Colon and rectum	836,720 (9.9%)	5,080,314	75 (10.5%)	1.48	80.2	1.58	0.93 (0.75-1.17)
Corpus uteri	250,987 (3.0%)	2,179,474	11 (1.5%)	0.50	13.3	0.61	0.83 (0.46-1.49)
Prostate	1,153,981 (13.6%)	9,095,242	123 (17.3%)	1.35	176.0	1.94	0.70 (0.59-0.83)
Skin, non-basal	494,208 (5.8%)	4,146,605	9 (1.3%)	0.22	21.8	0.53	0.41 (0.21-0.79)
Soft tissue including heart	51,819 (0.6%)	350,729	1 (0.1%)	0.29	2.47	0.70	0.41 (0.06-2.88)
Ovary	131,819 (1.6%)	754,837	0 (0.0%)	0	3.29	0.44	NA
Testis	53,702 (0.6%)	630,100	0 (0.0%)	0	1.15	0.18	NA
Small intestine	29,300 (0.3%)	144,653	0 (0.0%)	0	1.32	0.91	NA
Bones and joints	16,674 (0.2%)	129,231	0 (0.0%)	0	0.40	0.31	NA

Supplementary table 4 Mortality from septicemia among patients diagnosed with cancer between 1975 and 2016 in SEER 18 registries by anatomic sites.

Anatomic sites	No. of patients with cancer (%)	Total person years of follow-up	Death from septicemia				SMR (95% CI)
			Patients with cancer		General population		
			No. of observed deaths (%)	Mortality rates (per 100,000 person-years)	No. of expected deaths	Mortality rates (per 100,000 person-years)	
All	8,471,051 (100.0%)	51,747,254	28,765 (100.0%)	55.6	11571.6	22.4	2.49 (2.46-2.51)
Acute lymphocytic leukemia	30,933 (0.4%)	234,167	54 (0.2%)	23.1	3.2	1.4	16.8 (12.9-22.0)
Acute myeloid leukemia	61,060 (0.7%)	144,730	172 (0.6%)	118.8	14.9	10.3	11.6 (10.0-13.4)
Liver	118,324 (1.4%)	178,460	377 (1.3%)	211.3	38.2	21.4	9.87 (8.92-10.9)
Brain	123,661 (1.5%)	459,463	217 (0.8%)	47.2	25.8	5.6	8.41 (7.36-9.61)
Pancreas	195,663 (2.3%)	184,030	438 (1.5%)	238.0	58.5	31.8	7.48 (6.82-8.22)
Hodgkin lymphoma	53,532 (0.6%)	547,268	147 (0.5%)	26.9	20.8	3.8	7.07 (6.01-8.31)
Esophagus	73,170 (0.9%)	136,295	271 (0.9%)	198.8	40.3	29.6	6.72 (5.96-7.57)
Cervix uteri	87,411 (1.0%)	766,854	293 (1.0%)	38.2	48.1	6.3	6.10 (5.44-6.84)
Testis	53,702 (0.6%)	630,100	63 (0.2%)	10.0	10.7	1.7	5.87 (4.58-7.51)
Bones and joints	16,674 (0.2%)	129,231	40 (0.1%)	31.0	6.9	5.4	5.78 (4.24-7.88)
Kaposi sarcoma	22,244 (0.3%)	98,175	54 (0.2%)	55.0	11.3	11.5	4.80 (3.67-6.26)
Stomach	138,776 (1.6%)	362,179	516 (1.8%)	142.5	112.9	31.2	4.57 (4.19-4.98)
Lung and bronchus	965,341 (11.4%)	1,812,077	2,296 (8.0%)	126.7	526.8	29.1	4.36 (4.18-4.54)
Small intestine	29,300 (0.3%)	144,653	145 (0.5%)	100.2	35.1	24.3	4.13 (3.51-4.86)
Chronic myeloid leukemia	29,392 (0.3%)	133,063	102 (0.4%)	76.7	24.9	18.7	4.10 (3.38-4.98)
Myeloma	101,626 (1.2%)	351,116	451 (1.6%)	128.4	111.4	31.7	4.05 (3.69-4.44)
Oral cavity and pharynx	194,033 (2.3%)	1,125,688	780 (2.7%)	69.3	198.9	17.7	3.92 (3.66-4.21)
Ovary	131,819 (1.6%)	754,837	336 (1.2%)	44.5	89.4	11.8	3.76 (3.38-4.18)
Larynx	69,152 (0.8%)	452,396	358 (1.2%)	79.1	97.5	21.6	3.67 (3.31-4.07)

Anus	34,322 (0.4%)	205,924	116 (0.4%)	56.3	33.6	16.3	3.45 (2.88-4.14)
Corpus uteri	250,987 (3.0%)	2,179,474	1,008 (3.5%)	46.2	327.1	15.0	3.08 (2.90-3.28)
Non-Hodgkin lymphoma	311,485 (3.7%)	1,782,298	1,144 (4.0%)	64.2	382.7	21.5	2.99 (2.82-3.17)
Vulva	48,635 (0.6%)	437,415	168 (0.6%)	38.4	57.1	13.1	2.94 (2.53-3.42)
Kidney and renal pelvis	219,761 (2.6%)	1,257,816	777 (2.7%)	61.8	270.2	21.5	2.88 (2.68-3.09)
Colon and rectum	836,720 (9.9%)	5,080,314	4,205 (14.6%)	82.8	1517.0	29.9	2.77 (2.69-2.86)
Urinary bladder	310,644 (3.7%)	2,115,298	1,697 (5.9%)	80.2	687.8	32.5	2.47 (2.35-2.59)
Soft tissue including heart	51,819 (0.6%)	350,729	121 (0.4%)	34.5	49.5	14.1	2.45 (2.05-2.92)
Eye and orbit	16,780 (0.2%)	141,603	57 (0.2%)	40.3	24.1	17.0	2.37 (1.83-3.07)
Endocrine system	243,115 (2.9%)	1,955,341	370 (1.3%)	18.9	160.1	8.2	2.31 (2.09-2.56)
Other nervous system	124,837 (1.5%)	617,984	378 (1.3%)	61.2	164.4	26.6	2.30 (2.08-2.54)
Chronic lymphocytic leukemia	75,640 (0.9%)	469,838	338 (1.2%)	71.9	154.8	33.0	2.18 (1.96-2.43)
Breast	1,385,735 (16.4%)	12,017,682	3,770 (13.1%)	31.4	2060.8	17.1	1.83 (1.77-1.89)
Prostate	1,153,981 (13.6%)	9,095,242	4,519 (15.7%)	49.7	3093.6	34.0	1.46 (1.42-1.50)
Skin, non-basal	494,208 (5.8%)	4,146,605	995 (3.5%)	24.0	752.3	18.1	1.32 (1.24-1.41)

Supplementary table 5 Mortality from other infectious and parasitic diseases including HIV among patients diagnosed with cancer between 1975 and 2016 in SEER 18 registries by anatomic sites.

Anatomic sites	No. of patients with cancer (%)	Total person years of follow-up	Death from other infectious and parasitic diseases including HIV				
			Patients with cancer		General population		SMR (95% CI)
			No. of observed deaths (%)	Mortality rates (per 100,000 person-years)	No. of expected deaths	Mortality rates (per 100,000 person-years)	
All	8,471,051 (100.0%)	51,747,254	43,250 (100.0%)	83.6	5,559.8	10.7	7.78 (7.71-7.85)
Kaposi sarcoma	22,244 (0.3%)	98,175	12,329 (28.5%)	12,558.2	6.99	7.12	1,764.6 (1,733.7-1,796.0)
Liver	118,324 (1.4%)	178,460	3,712 (8.6%)	2,080.0	24.6	13.8	150.9 (146.1-155.8)
Acute lymphocytic leukemia	30,933 (0.4%)	234,167	162 (0.4%)	69.2	3.20	1.37	50.6 (43.4-59.0)
Anus	34,322 (0.4%)	205,924	908 (2.1%)	440.9	19.0	9.22	47.8 (44.8-51.0)
Hodgkin lymphoma	53,532 (0.6%)	547,268	738 (1.7%)	134.9	16.2	2.97	45.4 (42.3-48.8)
Non-Hodgkin lymphoma	311,485 (3.7%)	1,782,298	8,369 (19.4%)	469.6	194.3	10.9	43.1 (42.2-44.0)
Acute myeloid leukemia	61,060 (0.7%)	144,730	334 (0.8%)	230.8	9.08	6.27	36.8 (33.0-40.9)
Chronic myeloid leukemia	29,392 (0.3%)	133,063	174 (0.4%)	130.8	12.9	9.66	13.5 (11.7-15.7)
Brain	123,661 (1.5%)	459,463	220 (0.5%)	47.9	18.6	4.05	11.8 (10.4-13.5)
Cervix uteri	87,411 (1.0%)	766,854	287 (0.7%)	37.4	28.0	3.64	10.3 (9.15-11.5)
Myeloma	101,626 (1.2%)	351,116	467 (1.1%)	133.0	50.3	14.3	9.29 (8.49-10.2)
Testis	53,702 (0.6%)	630,100	139 (0.3%)	22.1	17.3	2.75	8.03 (6.80-9.48)
Esophagus	73,170 (0.9%)	136,295	162 (0.4%)	118.9	20.2	14.9	8.00 (6.86-9.33)
Vulva	48,635 (0.6%)	437,415	209 (0.5%)	47.8	27.1	6.20	7.71 (6.73-8.83)
Pancreas	195,663 (2.3%)	184,030	204 (0.5%)	110.9	27.3	14.8	7.48 (6.52-8.57)
Lung and bronchus	965,341 (11.4%)	1,812,077	1,807 (4.2%)	99.7	247.1	13.6	7.31 (6.98-7.66)

Chronic lymphocytic leukemia	75,640 (0.9%)	469,838	408 (0.9%)	86.8	70.1	14.9	5.82 (5.29-6.42)
Bones and joints	16,674 (0.2%)	129,231	26 (0.1%)	20.1	4.64	3.59	5.61 (3.82-8.24)
Oral cavity and pharynx	194,033 (2.3%)	1,125,688	644 (1.5%)	57.2	115.3	10.2	5.58 (5.17-6.03)
Stomach	138,776 (1.6%)	362,179	265 (0.6%)	73.2	51.1	14.1	5.18 (4.59-5.85)
Larynx	69,152 (0.8%)	452,396	244 (0.6%)	53.9	51.2	11.3	4.76 (4.20-5.40)
Soft tissue including heart	51,819 (0.6%)	350,729	103 (0.2%)	29.4	27.0	7.68	3.82 (3.15-4.64)
Small intestine	29,300 (0.3%)	144,653	65 (0.2%)	44.9	17.3	12.0	3.76 (2.95-4.79)
Ovary	131,819 (1.6%)	754,837	166 (0.4%)	22.0	45.2	5.99	3.67 (3.16-4.28)
Kidney and renal pelvis	219,761 (2.6%)	1,257,816	519 (1.2%)	41.3	144.5	11.5	3.59 (3.30-3.91)
Corpus uteri	250,987 (3.0%)	2,179,474	472 (1.1%)	21.7	159.8	7.33	2.95 (2.70-3.23)
Eye and orbit	16,780 (0.2%)	141,603	37 (0.1%)	26.1	13.1	9.25	2.83 (2.05-3.90)
Colon and rectum	836,720 (9.9%)	5,080,314	1,861 (4.3%)	36.6	663.0	13.1	2.81 (2.68-2.94)
Cranial nerves other nervous system	124,837 (1.5%)	617,984	227 (0.5%)	36.7	83.9	13.6	2.70 (2.37-3.08)
Urinary bladder	310,644 (3.7%)	2,115,298	820 (1.9%)	38.8	310.8	14.7	2.64 (2.46-2.82)
Endocrine system	243,115 (2.9%)	1,955,341	269 (0.6%)	13.8	102.4	5.24	2.63 (2.33-2.96)
Breast	1,385,735 (16.4%)	12,017,682	2,188 (5.1%)	18.2	959.1	7.98	2.28 (2.19-2.38)
Skin, non-basal	494,208 (5.8%)	4,146,605	765 (1.8%)	18.4	404.1	9.75	1.89 (1.76-2.03)
Prostate	1,153,981 (13.6%)	9,095,242	2,275 (5.3%)	25.0	1,446.0	15.9	1.57 (1.51-1.64)